Medication-related osteonecrosis of the jaws associated with intravitreal administration of ranibizumab.
Anti-angiogenic agent
MRONJ
Ranibizumab
Journal
International journal of oral and maxillofacial surgery
ISSN: 1399-0020
Titre abrégé: Int J Oral Maxillofac Surg
Pays: Denmark
ID NLM: 8605826
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
29
03
2020
revised:
05
04
2020
accepted:
25
05
2020
pubmed:
4
7
2020
medline:
25
11
2020
entrez:
4
7
2020
Statut:
ppublish
Résumé
Medication-related osteonecrosis of the jaws (MRONJ) is a well-known complication that, in the majority of cases, is related to antiresorptive agents. Numerous articles have described cases of MRONJ in bisphosphonate-naïve patients treated with anti-angiogenic agents administered via various routes. A single case of MRONJ after intravitreal injection of bevacizumab has been reported. We report a case of MRONJ after intravitreal injection of a different anti-angiogenic agent - ranibizumab - for the treatment of neovascular age-related macular degeneration, in a bisphosphonate-naïve patient. Although it may be a rare complication, patients treated with multiple doses of anti-angiogenic agents should be monitored for the possible early diagnosis of MRONJ.
Identifiants
pubmed: 32616306
pii: S0901-5027(20)30204-6
doi: 10.1016/j.ijom.2020.05.017
pii:
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Bone Density Conservation Agents
0
Bevacizumab
2S9ZZM9Q9V
Ranibizumab
ZL1R02VT79
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
1589-1591Informations de copyright
Copyright © 2020 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.